DNPUF - Sumitomo Dainippon Pharma Co., Ltd.

Other OTC - Other OTC Delayed Price. Currency in USD
14.95
+0.70 (+4.91%)
At close: 11:28AM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close14.25
Open14.95
Bid0.00 x 0
Ask0.00 x 0
Day's Range14.95 - 14.95
52 Week Range12.15 - 21.55
Volume300
Avg. Volume279
Market Cap5.804B
Beta (5Y Monthly)0.58
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.26 (1.82%)
Ex-Dividend DateMar 30, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      U.S. FDA approves Parkinson's treatment from Sunovion Pharma

      The U.S. Food and Drug Administration on Thursday approved a sublingual film from Sunovion Pharmaceuticals Inc, a unit of Japan-based Sumitomo Dainippon , for the treatment of "off" episodes in patients with Parkinson's disease, according to a label published by the agency. Parkinson's disease is a nervous system disorder in which patients suffer from motor fluctuations which oscillate between "off" times, a state of decreased mobility, and "on" times, or periods when the medication is working and symptoms are controlled.

    • A Duo of Underperforming Holdings to Ease Up On
      GuruFocus.com

      A Duo of Underperforming Holdings to Ease Up On

      They have fallen behind in recent years compared to the market Continue reading...

    • Reuters

      Sumitomo Dainippon Pharma investing $3 billion in Swiss Roivant in overseas push

      Japan's Sumitomo Dainippon Pharma Co will pay $3 billion for a 10% stake in Swiss drugmaker Roivant Sciences Ltd and interests in five of its biopharmaceutical businesses, the two companies said on Friday. The deal, which will open up new drug lines for Sumitomo Dainippon, will also give it the option to acquire interests in an additional six businesses, as well as access to Roivant's technology platforms, they said in a statement. It comes as Sumitomo Dainippon's schizophrenia treatment Latuda is due to lose its U.S. market exclusivity in 2023.